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ABStrAct                        The aim of this experiment was to study the effects of the antioxidant drug 
U-74389G on rat model, particularly in ischemia reperfusion (IR) protocol. The beneficial or other 
effects of that molecule were studied pathologically using endometrial edema (EE) lesions. Forty 
rats were used of mean weight 231.875 gr. EE lesions were evaluated 60 min after reperfusion 
(groups A and C) and 120 min after reperfusion (groups B and D), with administration of the 
drug U-74389G in groups C and D. Results were that U-74389G administration non-significantly 
decreased without lesions the EE scores by 0.41 [-1.00 - 0.17] (p= 0.1607). This finding was in 
accordance with the results of Wilcoxon signed-rank test (p= 0.5229). Reperfusion time non-
significantly increased without lesions the EE scores by 0.21 [-0.38 - 0.81] (p= 0.4701), also in 
accordance with Wilcoxon signed-rank test (p= 0.1022). However, U-74389G administration and 
reperfusion time together non-significantly decreased without lesions the EE scores by 0.17 
[-0.53 - 0.18] (p= 0.3383). Results of this study indicate that U-74389G administration hardly 
non-significantly decreases without lesions the EE within short-term time context of 2 hours.
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Tissue ischemia and reperfusion (IR) remain one of the 
main causes of permanent or transient damage with serious 
implications on adjacent organs and certainly on patients’ 
health. The use of antioxidant substances has been a research 
subject for many years. However, even if important progress 
has been made, satisfactory answers have not been given 
yet to fundamental questions, such as, how much powerful 
should an antioxidant be, when should it be administered, 
and in which dosage. The particularly satisfactory action 
of the antioxidant U-74389G in tissue protection has been 
noted in several performed experiments. Since a careful 
literature search (PubMed - Medline) was conducted, it was 
realized that this certain antioxidant has been tried in IR 
experiments. However, just few relative reports were found, 
not covering completely this particular matter. Also, a lot of 
publications addressed trials of other similar molecules of 
aminosteroids (lazaroids) to which the studied molecule also 
belongs to. U-74389G or better 21-[4-(2,6-di-1-pyrrolidinyl-
4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-
dione maleate salt (Cayman Chemical Product Catalog) is 
an antioxidant which prevents both arachidonic acid-induced 
and iron-dependent lipid peroxidation. It protects against 
IR injury in animal heart, liver, and kidney models. These 
membrane-associating antioxidants (Shi et al. 1995) are 
particularly effective in preventing permeability changes in 
brain microvascular endothelial cells monolayers. The same 
authors (Tsompos et al. 2014) found a light non-significant 
decline in chloride serum levels in related IR injury experi-
ments in rats by 0.58%+0.77% (p=0.4533) 1h after reperfu-
sion, by 0.97%+0.53% (p=0.0879) 1.5h after reperfusion, by 
0.75%+0.38% (p=0.0159) after time and drug interaction and 
by 1.36%+0.76% (p=0.1113) 2h after reperfusion.
The aim of this experimental study was to examine the 
effect of the antioxidant drug U-74389G on rat model and 
particularly in a uterus IR protocol. The beneficial effect or 
non-effectiveness of that molecule was studied by evaluating 
mean endometrial edema (EE) lesions.
Materials and Methods
Animal preparation
This experimental study was approved by Scientific Com-
mittee of Ippokrateion General Hospital, Athens University 
and by Veterinary Address of East Attiki Prefecture under 
3693/12-11-2010 & 14/10-1-2012 decisions. Institutional 
and national guide for the care and use of laboratory animals 
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was followed. This experimental study was carried out at the 
Experimental Research Center of ELPEN Pharmaceuticals 
Co. Inc. S.A. at Pikermi, Attiki. All settings needed for the 
study including consumables, equipment and substances used, 
were provided by them. Albino female Wistar rats were used 
in accordance with accepted standards of humane animal 
care. They spent 7 days in laboratory before experimentation 
with an easy access to water and food. The experiment was 
acute, that is, the animal usage was completed by following 
experimental set of times without awakening and preserva-
tion of the rodents. They were randomly assigned to four 
experimental groups (10 animals in each group). Group A: 
Ischemia for 45 min followed by reperfusion for 60 min. 
Group B: Ischemia for 45 min followed by reperfusion for 
120 min. Group C: Ischemia for 45 min followed immediately 
by U-74389G intravenous (IV) administration and reperfu-
sion for 60 min. Group D: Ischemia for 45 min followed im-
mediately by U-74389G IV administration and reperfusion 
for 120 min. The molecule U-74389G was administered in 
a dose of: 10 mg/kg body weight of the animal. The experi-
ment was beginning by prenarcosis and general anesthesia 
administration to the animals. Their electrocardiogram and 
acidometry were continuously monitored. The inferior aorta 
was prepared so as its blood flow, it could be excluded by 
forceps. After exclusion, the protocol of IR was applied, ex-
actly as is described in experimental groups. The molecules 
were administered at the time of reperfusion, through inferior 
vena cava catheterization, which had been carried out after 
general anesthesia. The EE evaluation was performed at 60 
min after reperfusion for groups A and C and at 120 min after 
reperfusion for groups B and D.
Protocol of the experiment
The experimental rats were given general anesthesia by initial 
intramuscular (IM) administration of 0.5 cc of a compound, 
constituting 0.25 cc xylazine, [25 cc, 20mg/cc] and 0.25 cc 
ketamine hydrochloride [1000, 100mg/cc, 10cc]. 0.03 cc bu-
torphanol [10mg/cc, 10cc] anesthetic agent was administered 
subcutaneously (SC) before laparotomy. Continuous oxygen 
supply was administered during the whole experiment. 
Ischemia was caused by clamping inferior aorta over renal 
arteries for 45 min after laparotomic access. Reperfusion was 
achieved by removing the clamp and inferior aorta patency 
re-establishment. Forty (40) female Wistar albino rats were 
used with a mean weight of 231.875 gr [Std. Dev: 36.59703 
gr], with min weight ≥ 165 gr and max weight < 320 gr. Rats 
weight could be potentially a confusing factor, e.g. fatter rats 
to have greater EE thickness. This suspicion will be investi-
gated. Also, detailed histopathological (Osmanağaoğlu et al. 
2012)  study (pathology) and grading of edema findings was 
performed by scores, this is: 0 when lesions were not found, 1 
when mild lesions were found, 2 when moderate lesions were 
found and 3 when serious lesions were found. The previous 
grading is transformed as follows: (0-0.499) without lesions, 
(0.5-1.499) the mild lesions, (1.5 -2.499) the moderate lesions 
and (2.5-3) the serious lesions damage, because the study 
concerns score ranges rather than point scores.
Model of ischemia-reperfusion injury
Control groups: 20 control rats of mean weight 252.5 gr [Std. 
Dev: 39.31988 gr] were subjected to ischemia for 45 min 
followed by reperfusion. 
Group A: 10 controls rats of mean weight 243 gr [Std. 
Dev: 45.77724 gr], mean mild EE score 1.2 [Std. Dev: 0.78] 
were subjected to 60 min reperfusion (Table 1).  
Group B: 10 controls rats of mean weight 262 gr [Std. 
Dev: 31.10913 gr], mean mild EE score 1.3 [Std. Dev: 1.15] 
(Table 1) were subjected to 120 min reperfusion (Table 1).    
Lazaroid (L) group: 20 rats of mean weight 211.25 gr 
[Std. Dev: 17.53755 gr] were subjected to ischemia for 45 
min followed by reperfusion in the beginning of which 10 mg 
U-74389G/kg body weight were IV administered. 
Group C: 10 L rats of mean weight 212.5 gr [Std. Dev: 
17.83411 gr], mean mild EE score 0.7 [Std. Dev: 0.67] (Table 
1) were subjected to 60 min reperfusion (Table 1).   
 Group D: 10 L rats of mean weight 210 gr [Std. Dev: 
18.10463 gr], mean mild EE score 1 [Std. Dev: 1.05] (Table 
1) were subjected to 120 min reperfusion (Table 1).   
results
Every weight group of rats was compared initially with an-
other one from 3 remained groups applying statistical paired 
t-test (Table 1). Any emerging significant difference among 
EE scores will be investigated whether owed in the above 
mentioned significant weight correlations. Every EE scores 
rats groups initially were compared with other one from 3 
remained groups applying Wilcoxon signed-rank test (Table 
2). Applying generalized linear models (glm) with dependant 
variables of the EE scores and with independent variables of 
the U-74389G administration or without that, the reperfusion 
time and their interaction, resulted in: U-74389G administra-
Table 1. Weight and endometrial edema (EE) score mean levels 
and Std. Dev. of groups.
Groups Variable Mean Std. Dev
A Weigh 243 gr 45.77 gr
EE mild 1.2 0.78
B Weigh 262 gr 31.10 gr
EE mild 1.3 1.15
C Weigh 212.5 gr 17.83 gr
EE mild 0.7 0.67
D Weigh 210 gr 18.10 gr
EE mild 1 1.05
Std. Dev: standard deviation
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tion non-significantly decreased without lesions the EE scores 
by 0.4 [-0.99 - 0.19] (p= 0.1781). This finding was also in 
accordance with the result of Wilcoxon signed-rank test (p= 
0.1816). Reperfusion time non-significantly increased with-
out lesions the EE scores by 0.2 [-0.40 - 0.80] (p= 0.5046), 
approximately in accordance with Wilcoxon signed-rank 
test also increased without lesions by 0.3 [-0.87 - 0.27] (p= 
0.3330). However, U-74389G administration and reperfusion 
time together non-significantly decreased without lesions 
the EE scores by 0.16 [-0.52 - 0.19] (p= 0.3641). Reviewing 
above and Table 2, Table 3 sums up concerning the decreas-
ing influence of U-74389G in connection with reperfusion 
time. Inserting the weight of the rats also as an independent 
variable at glm analysis, a non-significant relation results in 
(p=0.4934), so further investigation is not needed. 
discussion
The following clinical situations show the association between 
ischemia and EE. Canisso et al (2013) detected a reduction 
in endometrial edema during progestagen treatment, which 
returned to normal after cessation of treatment similarly with 
effectively abolished estrous behavior response to the stallion 
within 24h which returned to the control level after cessation 
of treatment, in mares, being received progestagen treatment 
when confirmed in estrus. Ludwig (1982) considered difficult 
to describe the morphology of the endometrial reaction, thus, 
he evaluated the endometria of women with respect to stromal 
edema. Sridhar et al. (2000) considered amniotic membrane 
transplantation in chemical injury with severe limbal ischemia 
and in severe thermal injury in acute phase, as in an eye with 
opaque cornea, stromal edema, and scarring within the first 
few weeks of injury. Batra et al. (1995) observed prominent 
hypoplasia of the syncytium, stromal edema, ischemia find-
ings, increased basement membrane thickening and high 
villous edema scores statistically significant in numerous 
representative samples taken from premature placentas im-
mediately after delivery as compared to controls. 
EE is involved in endometrial cancer and infertility. Gaete 
et al (2012) have previously shown that an estradiol-like 
hypertrophy of uterine cells may not be associated with cell 
proliferation, uterine eosinophilia, or endometrial edema. 
However, estrogen-induced cell proliferation in the uterus 
increases the risk of cancer development. Gaete et al (2011) 
found that complete inhibition of estradiol-induced mitoses 
in uterine luminal epithelium, endometrial stroma, myome-
trium and RNA content are followed by partial inhibition 
estradiol-induced uterine eosinophilia and endometrial edema 
in prepubertal rats. Protection against estrogen-induced cell 
proliferation in uterus suggests the decrease of the risk for 
uterine cancer after hormone replacement therapy in cli-
macteric women. Canisso et al. (2013) detected a reduction 
in endometrial edema during progestagen treatment, which 
returned to normal after cessation of treatment in cyclic 
mares. Witte et al. (2012) induced endometritis associated 
with increased amounts of intrauterine (i.u.) fluid or viscous 
mucus in estrus detected by ovarian follicle >3.0 cm and 
endometrial edema, which may contribute to low fertility in 
mares. Integrity of epithelium was not affected.
conclusion
U-74389G administration hardly non-significantly decreases 
the EE within short-term time context of 2 hours. Perhaps, 
a longer study time may reveal clearer and more significant 
results. Also, a more detailed study of molecular pathway of 
antioxidant capacity involvement of U-74389G in edema is 
required.    
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Table 2. Statistical significance of mean values difference for 
groups (DG) after statistical paired t test application for weight 
and Wilcoxon signed-rank test for scores. 
DG Variable Difference p-value
A-B Weight -19 gr 0.2423
EE without lesions -0.1 0.8728
A-C Weight 30.5 gr 0.0674
EE mild 0.5 0.2212
A-D Weight 33 gr 0.0574
EE without lesions 0.2 0.5164
B-C Weight 49.5 gr 0.0019
EE mild 0.6 0.1573
B-D Weight 52 gr 0.0004
EE without lesions 0.3 0.4935
C-D Weight 2.5 gr 0.7043
EE without lesions -0.3 0.4818
DG: difference for groups 
Table 3. The decreasing influence of U-74389G in connection 
with reperfusion time.







mild 0.5 -1.18 - 0.18 1 h 0.2212 0.1451
without lesions 0.4 -0.99 - 0.19 1.5 h 0.1816 0.1781
without lesions 0.3 -1.34 - 0.74 2 h 0.4935 0.5525




Batra S, Sen R, Jain K, Gulati N (1995) Phase contrast microscopic evalu-
ation of placental pathology in premature gestation. Indian J Pathol 
Microbiol 38(4):407-411.
Canisso IF, Gallacher K, Gilbert MA, Korn A, Schweizer CM, Bedford-
Guaus SJ, Gilbert RO (2013) Preovulatory progestagen treatment in 
mares fails to delay ovulation. Vet J 197(2):324-328. 
Canisso IF, Gallacher K, Gilbert MA, Korn A, Schweizer CM, Bedford-
Guaus SJ, Gilbert RO (2013) Preovulatory progestagen treatment in 
mares fails to delay ovulation. Vet J 197(2):324-328. 
Cayman Chem Prod Cat https://www.caymanchem.com/app/template/
Product.vm/catalog/75860.
Gaete L, Tchernitchin AN, Bustamante R, Villena J, Lemus I, Gidekel M, 
Cabrera G, Astorga P (2012) Daidzein-estrogen interaction in the rat 
uterus and its effect on human breast cancer cell growth. J Med Food 
15(12):1081-1090. 
Gaete L, Tchernitchin AN, Bustamante R, Villena J, Lemus I, Gidekel M, 
Cabrera G, Carrillo O (2011) Genistein selectively inhibits estrogen-
induced cell proliferation and other responses to hormone stimulation 
in the prepubertal rat uterus. J Med Food 14(12):1597-1603. 
Ludwig H (1982) The morphologic response of the human endometrium to 
long-term treatment with progestational agents. Am J Obstet Gynecol 
142(6 Pt 2):796-808.
Osmanağaoğlu MA, Kesim M, Yuluğ E, Menteşe A, Karahan SC (2012) 
Ovarian-protective effects of clotrimazole on ovarian ischemia/reper-
fusion injury in a rat ovarian-torsion model. Gynecol Obstet Invest 
74(2):125-130.
Shi F, Cavitt J, Audus KL (1995) 21-aminosteroid and 2-(aminomethyl)
chromans inhibition of arachidonic acid-induced lipid peroxidation and 
permeability enhancement in bovine brain microvessel endothelial cell 
monolayers. Free Rad Biol Med 19(3):349-357.
Sridhar MS, Bansal AK, Sangwan VS, Rao GN (2000) Amniotic membrane 
transplantation in acute chemical and thermal injury. Am J Ophthalmol 
130(1):134-137.
Witte TS, Melkus E, Walter I, Senge B, Schwab S, Aurich C, Heuwieser W 
(2012) Effects of oral treatment with N-acetylcysteine on the viscosity 
of intrauterine mucus and endometrial function in estrous mares. The-
riogenology 78(6):1199-1208. 
Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A (2014) The 
effect of the antioxidant drug “U-74389G” on chloride during ischemia 
reperfusion injury in rats. Med Rev 50(2):40-44.
